Lausanne May 29th – The FDA awarded breakthrough therapy designation to Alexion Pharmaceuticals’ asfotase alfa as a treatment for perinatal-, infantile- and juvenile-onset forms of hypophosphatasia. Asfotase alfa is an enzyme replacement therapy designed to treat, prevent and reverse the complications of hypophosphatasia. MedicalDaily.com
